Breaking the persistence barrier: Alloplex Biotherapeutics to present phase 1 clinical durability data at the 11th annual Innate Killer Summit

Achieving durable responses in advanced oncology remains the most critical challenge for innate cell therapies. As the industry seeks to move beyond the limitations of singular genetic engineering, Alloplex Biotherapeutics today announced it will present data demonstrating how biological synergy can overcome tumor escape and NK cell exhaustion.

At the 11th Annual Innate Killer Summit, Scientific Founder and CEO Dr. Frank Borriello, MD, PhD, will address two key scientific tracks on Tuesday, March 24 and Wednesday, March 25, revealing how the company’s non-engineered approach has achieved significant clinical persistence.

The presentation will center on the ENLIST immune cell training platform: an ex vivo process that activates peripheral blood mononuclear cells (PBMCs) to produce SUPLEXA cells. These cells exhibit a hybrid immune phenotype with broad anti-tumor activity and have shown a pristine safety profile with zero drug-related SAEs.

Key Scientific and Strategic Highlights:

• Proven Clinical Durability: Discussion of Phase 1 observations where SUPLEXA cells demonstrated a median of 70+ weeks of stable disease in heavily pre-treated oncology patients.
• Tumor Microenvironment Modulation: Mechanistic evidence showing a fundamental “reset” of the host immune environment, characterized by the systemic reduction of myeloid-derived suppressor cells (MDSCs).

Details for Summit Attendees:

• 08:30 AM PT | Strategic Panel: Optimizing Efficacy & Durability in NK Cell Therapies to Maximize Patient Outcomes. Dr. Borriello will join industry leaders to evaluate the clinical insights shaping the future of innate cell therapies.
• 03:00 PM PT | Technical Presentation: Developing Next-Gen NK Cells to Boost Safety & Potency for More Effective Cancer Therapies. This session will detail the ENLIST platform’s ability to generate potent therapeutic cells via a streamlined manufacturing process designed for commercial scalability.

“Limited cell persistence is a key hurdle to long-term success in cell therapy,” said Dr. Borriello. “Our data suggests that by training the immune system to recognize a wide array of signals, we can achieve the durability that synthetic engineering often fails to deliver.”

Collaboration and Media Engagement

Dr. Borriello looks forward to engaging with stakeholders who have interest in collaborating on this first-of-its-kind lead autologous platform. Unlike traditional models, the ENLIST process was designed from inception for readily-scalable manufacturing, utilizing a standard 50ml blood draw to facilitate rapid clinical expansion.Summit attendees, members of the media and industry commentators are encouraged to reach out to the Alloplex team in advance to schedule briefings or visit Dr. Borriello’s Official Summit Speaker Profile for session locations and full abstract details.